Benefits of Pelargonium (Umcka)

Evidence-Based Benefits

• Bronchitis treatment — a Cochrane review by Timmer et al. (2013) of 10 RCTs found Pelargonium sidoides extract (EPs 7630) significantly reduced bronchitis symptom severity and duration compared to placebo, with good tolerability
• Antiviral mechanism — pelargonium extract interferes with viral hemagglutinin, preventing influenza and other respiratory viruses from attaching to and entering host cells. It also induces interferon production, enhancing antiviral defense
• Antibacterial adhesion inhibition — the prodelphinidins in pelargonium prevent bacteria from adhering to mucosal epithelial cells, reducing bacterial colonization and secondary infection risk during viral illness
• Immunomodulation — EPs 7630 stimulates macrophage phagocytic activity, enhances NK cell function, and increases production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and interferon-beta
• Mucus clearance — pelargonium extract increases ciliary beat frequency in bronchial epithelium, improving mucociliary clearance and helping the body expel pathogens and mucus from the airways

What the Research Says

Pelargonium sidoides has an unusually strong evidence base for a herbal remedy. The Cochrane review by Timmer et al. (2013) analyzed 10 RCTs and concluded that EPs 7630 is effective and well-tolerated for acute bronchitis. Matthys et al. (2003) conducted a pivotal double-blind, placebo-controlled RCT showing significant reductions in bronchitis symptom severity scores after 7 days of treatment. The extract is approved as a licensed phytomedicine in Germany — a regulatory status that requires demonstration of efficacy and safety through clinical trials. The multi-target mechanism (antiviral, antibacterial, immunomodulatory, mucociliary) provides a pharmacological rationale for its clinical effectiveness.

Related Conditions